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Background.  Like other streptococci, Streptococcus agalactiae typically has intrinsic low-28	  
level aminoglycoside resistance.  High-level gentamicin resistance was seen in two of 1125 29	  
isolates collected in the British Society for Antimicrobial Chemotherapy (BSAC) 30	  
Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both 31	  
isolated in 2014, were characterised. Methods. Identifications were by latex agglutination, 32	  
MICs by BSAC agar dilution, and sequencing by Illumina methodology. Results.  33	  
Gentamicin MICs were >1024 mg/L versus a species mode of 8 mg/L; both isolates also 34	  
were unusually ciprofloxacin resistant with MICs of 64 mg/L versus a species mode of 1 35	  
mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs 36	  
globally. Both had aac6’-aph2’’, carried by different transposons, explaining their 37	  
gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin 38	  
resistance. Conclusion. These are the first multiresistant S. agalactiae with the bifunctional 39	  
AAC(6’)-APH(2”) enzyme to be reported in the UK for over 10 years. Despite belonging to 40	  
the same clonal complex, the two isolates and their resistance transposons were distinct.   41	  
Both retained full susceptibility to penicillin, but any penicillin-gentamicin synergy is likely to 42	  
be lost. 43	  44	  
Introduction 44	  
Streptococcus agalactiae (Group B streptococcus, GBS) is an important agent of neonatal 45	  
sepsis. In 2010, the UK incidence was 0.41 cases /1000 live births, with a growing number 46	  
of adult septicaemias also recorded.1  Most clinical isolates belong to clonal complexes 47	  
(CCs) 1,10,17,19, 23 and, among these, CC17 is considered to have increased virulence 48	  
potential.2  Antibiotic resistance is not a major issue in the species. Penicillin remains the 49	  
treatment of choice and resistance is extremely rare, though strains with reduced 50	  
susceptibility are a growing problem in Japan.3 Tetracycline resistance is frequent,2 but is of 51	  
limited clinical relevance, given that tetracyclines are contra-indicated in neonates and their 52	  
expectant mothers, who form the largest patient groups.  Like all streptococci, GBS have 53	  
low-level intrinsic resistance to gentamicin, reflecting poor uptake; high-level resistance, 54	  
mediated by the bifunctional AAC(6’)-APH(2”) enzyme that is prevalent in enterococci and 55	  
staphylococci, has been reported on a few occasions in GBS in the UK4 and France,5 with 56	  
some recent proliferation in Argentina,6 but is considered still to be exceptional.  57	  
 Between 2001 and 2014, the BSAC Bacteraemia Surveillance Programme 58	  
examined 1125 S. agalactiae from over 70 UK and Irish sites.  In 2014, for the first time, we 59	  
identified two isolates of this species with high-level gentamicin resistance. They were 60	  
referred from separate hospitals, and both also were unusually resistant to ciprofloxacin. 61	  
These genomes of these organisms were sequenced to elucidate their relatedness and the 62	  
genetic bases of their resistance phenotypes. 63	  
 64	  
 Materials and methods 65	  
Isolates and susceptibility testing 66	  
The collection strategy for the BSAC Bacteraemia Surveillance Programme has been 67	  
described7.  Until 2008, 25 UK and Irish diagnostic laboratories contributed up to 10 68	  
consecutive β-haemolytic streptococci per annum; subsequently the number of laboratories 69	  
was increased to 40 and the number of isolates per site reduced to seven. There is some 70	  
turnover of collection laboratories, and 70 sites have participated during the period 71	  
reviewed (2001-14). On receipt by PHE, β-haemolytic streptococci are identified using the 72	  
Streptococcal Grouping Latex kit (Pro-Lab Diagnostics, Bromborough, UK) and MICs are 73	  
determined by BSAC agar dilution.8 The two highly-gentamicin-resistant isolates were 74	  
collected in 2014 at separate hospitals 70 miles (112 km) apart: BSB14107 was from a 28-75	  
year-old woman and was isolated in the January; BSB14238 was from a 33-year-old man 76	  
and was isolated in the April.  We do not have clinical details for the patients.   77	  
 78	  
Sequencing 79	  
Isolates were sequenced at PHE’s Genomic Service Delivery Unit on an Illumina HiSeq 80	  
2500 platform using the Nextera XT sample preparation method. In-silico MLST was 81	  
performed using the mapping-based tool MOST,9 with reference sequences downloaded 82	  
from the S. agalactiae MLST database.10 Antimicrobial resistance genes were detected  83	  
using a locally-curated database of resistance determinants and the in-house algorithm 84	  
‘GeneFinder’.11 Short reads were assembled into contigs using SPAdes12 and those 85	  
carrying the gentamicin resistance determinant were identified by BLAST. Coding 86	  
sequences were determined with Glimmer13 with functions inferred from homology 87	  
searches with BLAST. The genetic relatedness of the isolates was assessed by Single 88	  
Nucleotide Polymorphisms (SNP) analysis, as previously described.14 89	  
 90	  
Results and Discussion 91	  
Susceptibility   92	  
Among 3218 β-haemolytic streptococci collected from bacteraemic patients by the BSAC 93	  
Surveillance Programme from 2001-2014, 1125 were identified as S agalactiae. MIC 94	  
distributions for these are shown in Table 1. Isolates BSB14107 and BSB14238 were the 95	  
only two with high-level resistance to gentamicin and were among a small minority (7/1125) 96	  
with high-level ciprofloxacin resistance.  Both also were highly resistant to tetracycline, 97	  
though this trait was highly prevalent in the whole collection, with MICs >16 mg/L for 77.5% 98	  
of the isolates.  Both retained normal susceptibility to β-lactams and vancomycin (Table 1). 99	  
BSB14107 was highly resistant to both erythromycin and clindamycin (MICs >128 mg/L); 100	  
BSB14238 had low-level resistance to erythromycin (MIC 2 mg/L), but remained fully 101	  
susceptible to clindamycin (MIC 0.12 mg/L). 102	  
 103	  
Sequencing and strain characterisation  104	  
Based on in-silico MLST, using whole genome sequences, both resistant isolates belonged 105	  
to the ST19 clone, which occurs internationally. Nevertheless, their sequences differed by 106	  
at least 934 SNPs, indicating them to be distinct.  The phenotypes of both isolates (Table 1) 107	  
could be explained by the acquired resistance genes or mutations identified.  Both carried 108	  
aac(6’)-aph(2’’), explaining high-level gentamicin resistance; both also had chromosomal 109	  
gyrA[81:S-L];parC[79:S-Y] mutations, explaining high-level ciprofloxacin resistance. 110	  
Furthermore, both had tet(M), accounting for tetracycline resistance; this was embedded in 111	  
the same position in Tn916-like elements in both strains and was unlinked to aac(6’)-112	  
aph(2’’). BSB14107 additionally had mef(E), erm(B), msr(D), Isa(E) and lnu(B), all of which 113	  
contributed to high-level macrolide and lincosamide resistance, as observed in this strain. 114	  
BSB14238 had erm(TR), explaining low-level macrolide resistance; it also carried lnu(C), 115	  
but this gene does not reliably cause clindamycin resistance in streptococci15 and so is not 116	  
discordant with observed susceptibility.  117	  
 The aac(6’)-aph(2’’) gene was transposon-borne in both isolates, but the genetic 118	  
environments (Figure 1) differed between the two organisms. In BSB14107 the 119	  
arrangement most closely resembled that previously described from S. agalactiae SGB7616 120	  
though this strain did not carry aac(6’)-aph(2’’).  Specifically, aac(6’)-aph(2”) was located on 121	  
the same contig as a known mobile element carrying aadE and lnu(B) along with the 122	  
spectinomycin adenyltransferase determinant, spc; however, no direct association with 123	  
known mobile elements was apparent for aac(6’)-aph2” itself (figure 1a).  In BSB14238, 124	  
aac(6’)-aph(2”) was linked to the insertion element IS256, as previously described in (i) 125	  
Tn3706 from S. agalactiae isolated in France in 198717 and (ii) Tn4001 from 126	  
staphylococci.18 However, only the upstream copy of  IS256 was confirmed; downstream of 127	  
aac(6’)-aph(2”)we found only the end of the putative second IS256 copy; failure to detect 128	  
the entire element probably reflects problems inherent in resolving repeats in short-read 129	  
assemblies. 130	  
 In summary, S. agalactiae with high-level gentamicin resistance mediated by the 131	  
bifunctional AAC(6’)-APH(2”) enzyme have (re-)emerged in the UK. In is unknown whether 132	  
the isolates were imported or if they acquired their resistance transposons locally. Isolates 133	  
with this mechanism were reported in the country in 2002,4 but have not, to our knowledge, 134	  
been recorded subsequently. Despite belonging to ST19 and sharing exceptional 135	  
fluoroquinolone resistance, the present isolates and their resistance transposons were 136	  
distinct from each other: that in BSB14107 was distinct from any previously found in GBS.  137	  
Despite the organisms’ multiresistance, and their evident ability to cause infection in 138	  
the source patients, their wider clinical significance is uncertain. UK guidelines19 advocate 139	  
empirical penicillin plus gentamicin for neonatal sepsis, and similar regimens are widely 140	  
used international.  The general view in the UK is that the penicillin covers against GBS 141	  
whilst the gentamicin covers against Enterobacteriaceae, which are the other likely 142	  
pathogens in the setting. If this view is correct, high-level gentamicin resistance GBS will be 143	  
of little significance. A counter view is that gentamicin may potentiate penicillins in S. 144	  
agalactiae bacteraemia, as in streptococcal endocarditis. In this case high-level resistance 145	  
would be predicated to abrogate this synergy, potentially impacting upon outcomes. There 146	  
is, however, scant clinical evidence to support this latter, view and a recent in vitro analysis 147	  
found that gentamicin only gave a small acceleration of penicillin-mediated killing, without 148	  
convincing synergy.20   A separate and less debatable risk is that GBS may become a 149	  
vector of transposons encoding AAC(6’)-APH(2”), facilitating its widening dissemination. 150	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